HLA
TPST icon

Hamilton Lane Advisors’s Tempest Therapeutics TPST Stock Holding History

Hamilton Lane Advisors’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-6
Closed -$569K – 69
2015
Q1 		$569K Buy
+6
New +$799K 0.26% 37

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OH
Orbis Holdings Hamilton, Bermuda $12.8B AUM 8.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Hamilton Lane Advisors's TPST Position: Q2 2015 in Review

Hamilton Lane Advisors sold out of Tempest Therapeutics (TPST) in Q2 2015, closing a stake of 6 shares — an estimated $569K sold.

Hamilton Lane Advisors first reported a position in TPST in Q1 2015 and held it in 1 quarter. The position peaked at $569K in Q1 2015. 92 funds tracked by Wall St. Rank hold TPST as of Q2 2015.

  • Hamilton Lane Advisors reported no remaining Tempest Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Hamilton Lane Advisors sold 6 Tempest Therapeutics shares in Q2 2015, an estimated $569K.
  • Hamilton Lane Advisors first reported a position in Tempest Therapeutics in Q1 2015 and held it in 1 quarter.
  • Hamilton Lane Advisors's Tempest Therapeutics position peaked at $569K in Q1 2015.
  • 92 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q2 2015.

Based on Hamilton Lane Advisors's 13F filing for Q2 2015, filed 23 Jul 2015.